Viz.ai to Collaborate With Guardant Health to Improve Lung Cancer Detection, Diagnosis, and Treatment

Viz.ai and Guardant Health (GH) announced a proposed collaboration to improve lung cancer care through the integration of AI and genomic insights.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/14/2025 - 03:56 PM EST

Proposed collaboration aims to integrate cutting-edge AI and genomic insights to advance guideline-directed medical therapy

SAN FRANCISCO--(BUSINESS WIRE)-- Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a proposed collaboration with Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, to address challenges in lung cancer care. The collaboration aims to help oncologists diagnose lung cancer earlier and make more informed treatment decisions to improve patient outcomes, reflecting the companies’ shared commitment to leveraging technology to close critical gaps in cancer care and streamline the patient journey.

“This collaboration represents a promising step forward in the fight against lung cancer and reflects our commitment to expanding Viz.ai’s impact in oncology,” said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “Together, we have the opportunity to harness the power of AI and genomics to ensure patients receive timely, personalized, and effective care.”

Nearly 40% of lung cancer patients are estimated not to be receiving guideline-directed medical therapy.¹ Delays in diagnosis, testing, and appropriate treatment increase the risk of lung cancer progression to advanced-stage disease and can contribute to higher mortality rates. The intent of the proposed collaboration between Viz.ai and Guardant is to address clinical practice gaps along the lung cancer patient journey by facilitating timely biomarker testing with the Guardant360® CDx liquid biopsy, thereby accelerating time to precision diagnosis and optimal treatment selection.

The Viz.ai One platform leverages machine learning algorithms to analyze data from imaging, the EHR and other tests and deliver real-time, actionable insights and automated assessments to accelerate diagnosis and treatment. Viz.ai acts as a safety net in 1,700 hospitals to automatically identify patients with disease and direct them to the right specialist and the right treatment.

Learn more about Viz.ai’s commitment to lung cancer here.

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700 hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Blom EF, Ten Haaf K, Arenberg DA, de Koning HJ. Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States. Ann Am Thorac Soc. 2020 Feb;17(2):186-194. doi: 10.1513/AnnalsATS.201901-094OC. PMID: 31672025; PMCID: PMC6993802.